217 related articles for article (PubMed ID: 33598797)
1. The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors.
Meirovitz A; Shouchane-Blum K; Maly A; Bersudski E; Hirshoren N; Abrams R; Popovtzer A; Orevi M; Weinberger J
J Cancer Res Clin Oncol; 2021 May; 147(5):1335-1340. PubMed ID: 33598797
[TBL] [Abstract][Full Text] [Related]
2. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor imaging with [
Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275
[TBL] [Abstract][Full Text] [Related]
4. Caveolin-1 overexpression in benign and malignant salivary gland tumors.
Jaafari-Ashkavandi Z; Ashraf MJ; Nazhvani AD; Azizi Z
Tumour Biol; 2016 Feb; 37(2):1863-9. PubMed ID: 26323261
[TBL] [Abstract][Full Text] [Related]
5. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
6. Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors.
Tadbir AA; Pardis S; Ashkavandi ZJ; Najvani AD; Ashraf MJ; Taheri A; Zadeh MA; Sardari Y
Asian Pac J Cancer Prev; 2012; 13(10):5155-9. PubMed ID: 23244127
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
8. MCM3 as a novel diagnostic marker in benign and malignant salivary gland tumors.
Ashkavandi ZJ; Najvani AD; Tadbir AA; Pardis S; Ranjbar MA; Ashraf MJ
Asian Pac J Cancer Prev; 2013; 14(6):3479-82. PubMed ID: 23886132
[TBL] [Abstract][Full Text] [Related]
9. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.
Kiviniemi A; Gardberg M; Autio A; Li XG; Heuser VD; Liljenbäck H; Käkelä M; Sipilä H; Kurkipuro J; Ylä-Herttuala S; Knuuti J; Minn H; Roivainen A
Acta Oncol; 2014 Aug; 53(8):1125-34. PubMed ID: 24957558
[TBL] [Abstract][Full Text] [Related]
12. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.
Rachinger W; Stoecklein VM; Terpolilli NA; Haug AR; Ertl L; Pöschl J; Schüller U; Schichor C; Thon N; Tonn JC
J Nucl Med; 2015 Mar; 56(3):347-53. PubMed ID: 25635133
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of SSTR2 Expression Assessed by
Fonti R; Panico M; Pellegrino S; Pulcrano A; Vastarella LA; Torbati AHM; Giuliano M; Palmieri G; De Placido S; Del Vecchio S
J Nucl Med; 2022 Oct; 63(10):1509-1514. PubMed ID: 35273092
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic analysis of [
Bashir A; Vestergaard MB; Binderup T; Broholm H; Marner L; Ziebell M; Fugleholm K; Mathiesen T; Kjær A; Law I
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2577-2588. PubMed ID: 32170347
[TBL] [Abstract][Full Text] [Related]
15. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.
Miederer M; Seidl S; Buck A; Scheidhauer K; Wester HJ; Schwaiger M; Perren A
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):48-52. PubMed ID: 18807033
[TBL] [Abstract][Full Text] [Related]
16. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands.
Gibbons MD; Manne U; Carroll WR; Peters GE; Weiss HL; Grizzle WE
Laryngoscope; 2001 Aug; 111(8):1373-8. PubMed ID: 11568571
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Detection of Proliferative Marker Ki-67 in Benign and Malignant Salivary Gland Tumors.
Bussari S; Ganvir SM; Sarode M; Jeergal PA; Deshmukh A; Srivastava H
J Contemp Dent Pract; 2018 Apr; 19(4):375-383. PubMed ID: 29728539
[No Abstract] [Full Text] [Related]
18. Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours.
Vargas PA; Cheng Y; Barrett AW; Craig GT; Speight PM
J Oral Pathol Med; 2008 May; 37(5):309-18. PubMed ID: 18248354
[TBL] [Abstract][Full Text] [Related]
19. Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland.
Dincer N; Tezel GG; Sungur A; Himmetoglu C; Huebner K; Güler G
Oral Oncol; 2010 Mar; 46(3):195-9. PubMed ID: 20060354
[TBL] [Abstract][Full Text] [Related]
20. Human kallikrein 13 expression in salivary gland tumors.
Darling MR; Jackson-Boeters L; Daley TD; Diamandis EP
Int J Biol Markers; 2006; 21(2):106-10. PubMed ID: 16847813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
